Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $0.93 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.85 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -10.71%. A quarter ago, it was expected that this company would post a loss of $0.89 per share when it actually produced a loss of $0.90, delivering a surprise of -1.12%.Over the last four quarters, the com ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 CRINETICS PHARMACEUTICALS, INC. QUARTERLY REPORT ON FORM 10-Q For the Quarter Ended March 31, 2024 | --- | --- | |----------|-------| | | | | | | | | | | Item 1. | | | Item 1A. | | | Item 2. | | | | | | Item 3. | | | Item 4. | | | Item 5. | | | Item 6. | | Item 1. Condensed Financial Statemen ...

公司业绩 - CRNX股价在3月19日上涨了19.1%[1] - 公司报告了两项晚期研究中领先候选药物paltusotine的积极数据[1] - PATHFNDR-2研究达到了主要终点，显示出paltusotine治疗的患者中有56%达到了IGF-1水平≤正常上限的1.0倍[4] 产品研发 - PATHFNDR-2研究评估了paltusotine在患有肢端肥大症的参与者中的疗效和安全性[3] - CRNX表示paltusotine在PATHFNDR-2研究中整体耐受性良好，没有严重不良事件[5] - 公司管理层相信来自PATHFNDR-2研究的数据证实了paltusotine在未接受药物治疗的肢端肥大症患者中提供症状控制和生化控制的潜力[6] 未来计划 - CRNX目前正在对paltusotine进行另一项中期研究，用于治疗类癌综合征[12] - 公司计划在2024年下半年向FDA提交paltusotine用于肢端肥大症适应症的审批申请，预计在2025年在美国市场推出该产品[11]

Crinetics Pharmaceuticals, Inc. (CRNX)股价表现 - Crinetics Pharmaceuticals, Inc. (CRNX)股价在最近一个交易日上涨了19.1%，收于45.18美元[1] PATHFNDR-2研究结果 - Crinetics公司在第二个晚期研究（PATHFNDR-2）中取得了主要和所有关键次要终点，具有统计学意义，评估了其主力候选药物paltusotine治疗肢端肥大症的疗效和安全性，这导致了股价的突然上涨[2] 财报预期 - Crinetics公司预计在即将发布的财报中每股亏损0.84美元，同比增长1.2%，预计营收为820万美元，较去年同期下降了69.6%[3] 盈利预期调整 - Crinetics Pharmaceuticals的每股盈利预期在过去30天内上调了5.5%，这种正面的盈利预期趋势通常会转化为股价上涨[5]

Crinetics Pharmaceuticals新闻 - Crinetics Pharmaceuticals宣布了来自PATHFNDR-2的积极的头条结果，该研究是评估口服一次日服用的研究性药物paltusotine治疗肢端肥大症的两项第三阶段研究之一[1] - PATHFNDR-2研究结果显示，paltusotine在治疗肢端肥大症患者中表现出显著的疗效和安全性，且未出现严重不良事件[2] - Crinetics计划在2024年下半年向FDA提交NDA，为paltusotine的批准提供支持，以及为2025年的上市做准备[3]

paltusotine研究结果 - Crinetics Pharmaceuticals宣布了paltusotine在第二期类癌综合症研究中的积极结果[1] - paltusotine在研究中表现出快速和持续减少潮红发作和排便次数的效果[3] - paltusotine是第一种口服、每日一次的选择性靶向生长抑素受体2（SST2）激动剂，目前正在进行乳腺肥大症的第三期临床研究和类癌综合症的第二期临床研究[7]

SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that on March 10, 2024, the Compensation Committee of Crinetics' Board of Directors granted non-qualified stock option awards to purchase an aggregate of 42,450 shares of its common stock to five new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the "2021 Inducement Plan"). The stock options were granted as inducements material to th ...

koya79 Financial and Clinical Progress Positions Crinetics for Market Leadership Much has changed at Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) since my first look nearly a year ago. Back then, I expressed concern over their oral solution for acromegaly and made the argument that paltusotine, by the nature of its oral administration, would likely not be able to replicate the efficacy and safety of existing subcutaneous drugs like octreotide. Nonetheless, I did recognize the potential of Crinetics' dr ...

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q4 2023 Earnings Conference Call February 28, 2024 4:30 PM ET Company Participants Corey Davis - LifeSci Advisors Scott Struthers - Founder and Chief Executive Officer Alan Krasner - Chief Endocrinologist Marc Wilson - Chief Financial Officer Jim Hassard - Chief Commercial Officer Conference Call Participants Joseph Schwartz - Leerink Partners Yasmeen Rahimi - Piper Sandler Jeff Hung - Morgan Stanley Cory Jubinville - LifeSci Brian Skorney - Baird Douglas Tsao - ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38583 Crinetics Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 26-3744114 (State or other juris ...